{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:49Z","timestamp":1787026729335,"version":"build-2736575974"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Regulatory T cells (Tregs), possess a pivotal function in the maintenance of immune homeostasis. The dysregulated activity of Tregs has been associated with the onset of autoimmune diseases and cancer. Hence, Tregs are promising targets for interventions aimed at steering the immune response toward the desired path, either by augmenting the immune system to eliminate infected and cancerous cells or by dampening it to curtail the damage to self-tissues in autoimmune disorders. The activation of Tregs has been observed to have a potent immunosuppressive effect against T cells that respond to self-antigens, thus safeguarding our body against autoimmunity. Therefore, promoting Treg cell stability presents a promising strategy for preventing or managing chronic inflammation that results from various autoimmune diseases. On the other hand, Tregs have been found to be overactivated in several forms of cancer, and their role as immune response regulators with immunosuppressive properties poses a significant impediment to the successful implementation of cancer immunotherapy. However, the targeting of Tregs in a systemic manner may lead to the onset of severe inflammation and autoimmune toxicity. It is imperative to develop more selective methods for targeting the function of Tregs in tumors. In this review, our objective is to elucidate the function of Tregs in tumors and autoimmunity while also delving into numerous therapeutic strategies for reprogramming their function. Our focus is on reprogramming Tregs in a highly activated phenotype driven by the activation of key surface receptors and metabolic reprogramming. Furthermore, we examine Treg-based therapies in autoimmunity, with a specific emphasis on Chimeric Antigen Receptor (CAR)-Treg therapy and T-cell receptor (TCR)-Treg therapy. Finally, we discuss key challenges and the future steps in reprogramming Tregs that could lead to the development of novel and effective cancer immunotherapies.<\/jats:p>","DOI":"10.3389\/fmed.2023.1244298","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:18:16Z","timestamp":1695860296000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Regulating the regulatory T cells as cell therapies in autoimmunity and cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Hamed","family":"Hosseinalizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rabiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Eghbalifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Klionsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.15283\/ijsc21032","article-title":"Therapeutic aspects of mesenchymal stem cell-based cell therapy with a focus on human amniotic epithelial cells in multiple sclerosis: a mechanistic review","volume":"14","author":"ArefNezhad","year":"2021","journal-title":"Int J Stem Cells"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.placenta.2018.06.008","article-title":"Immunomodulatory effects of human amniotic epithelial cells on naive CD4+ T cells from women with unexplained recurrent spontaneous abortion","volume":"71","author":"Motedayyen","year":"2018","journal-title":"Placenta"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.repbio.2018.04.002","article-title":"Human amniotic epithelial cells inhibit activation and pro-inflammatory cytokines production of naive CD4+ T cells from women with unexplained recurrent spontaneous abortion","volume":"18","author":"Motedayyen","year":"2018","journal-title":"Reprod Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.25002\/tji.2019.991","article-title":"Immunoregulatory effects of human amnion epithelial cells on natural killer and T cells in women with Recurrent Spontaneous Abortion (RSA)","volume":"7","author":"Khadem","year":"2019","journal-title":"Turk J Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/08820139.2020.1726381","article-title":"Modulation of Th17 proliferation and IL-17A gene expression by acetylated form of apigenin in patients with multiple sclerosis","volume":"50","author":"Rahmati","year":"2021","journal-title":"Immunol Investig"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/ph14121315","article-title":"The therapeutic potential of common herbal and nano-based herbal formulations against ovarian cancer: new insight into the current evidence","volume":"14","author":"Rezaei-Tazangi","year":"2021","journal-title":"Pharmaceuticals"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/cbin.11991","article-title":"Human umbilical cord mesenchymal stem cells: heralding an effective treatment against esophageal cancer?","volume":"47","author":"ArefNezhad","year":"2023","journal-title":"Cell Biol Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s11033-020-06115-w","article-title":"Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma","volume":"48","author":"Fathi","year":"2021","journal-title":"Mol Biol Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/08820139.2018.1498882","article-title":"Comparison of the percentage of regulatory T cells and their p-STAT5 expression in allergic and non-allergic common variable immunodeficiency patients","volume":"48","author":"Sadati","year":"2019","journal-title":"Immunol Investig"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/eji.201948470","article-title":"Regulatory T cell metabolism at the intersection between autoimmune diseases and cancer","volume":"50","author":"Kurniawan","year":"2020","journal-title":"Eur J Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-021-05868-2","article-title":"Impacts of Fc\u03b3RIIB and Fc\u03b3RIIIA gene polymorphisms on systemic lupus erythematous disease activity index","volume":"14","author":"Karimifar","year":"2021","journal-title":"BMC Res Notes"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/08820139.2019.1571506","article-title":"The effects of silymarin and cyclosporine A on the proliferation and cytokine production of regulatory T cells","volume":"48","author":"Keyhanmehr","year":"2019","journal-title":"Immunol Investig"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"039463202210784","DOI":"10.1177\/03946320221078476","article-title":"Changes in immune profile affect disease progression in hepatocellular carcinoma","volume":"36","author":"Fathi","year":"2022","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2058738419863238","DOI":"10.1177\/2058738419863238","article-title":"Regulatory T-cells and their impacts on cytokine profile of end-stage renal disease patients suffering from systemic lupus erythematosus","volume":"33","author":"Fathi","year":"2019","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/iji.12447","article-title":"Association of programmed death-1 gene polymorphisms with the risk of basal cell carcinoma","volume":"46","author":"Fathi","year":"2019","journal-title":"Int J Immunogenet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.25002\/tji.2019.1035","article-title":"Increased expression of lymphocyte activation gene-3 by regulatory T cells in multiple sclerosis patients with fingolimod treatment","volume":"7","author":"Sedaghat","year":"2019","journal-title":"Turk J Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2015.11.019","article-title":"Targeted mutations in Val101 and Arg27 interferon beta protein increase its transcriptional and translational activities","volume":"78","author":"Kay","year":"2016","journal-title":"Cytokine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.4049\/jimmunol.181.5.3137","article-title":"Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo1","volume":"181","author":"Radhakrishnan","year":"2008","journal-title":"J Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/imm.13058","article-title":"Treg programming and therapeutic reprogramming in cancer","volume":"157","author":"Moreno Ayala","year":"2019","journal-title":"Immunology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fimmu.2021.702726","article-title":"Regulatory T cells: barriers of immune infiltration into the tumor microenvironment","volume":"12","author":"Scott","year":"2021","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the role of the tumor vasculature in antitumor immunity and immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.celrep.2019.12.081","article-title":"Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance","volume":"30","author":"Sullivan","year":"2020","journal-title":"Cell Rep"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1002\/jcp.27553","article-title":"Contribution of regulatory T cells to cancer: a review","volume":"234","author":"Najafi","year":"2019","journal-title":"J Cell Physiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"19446","DOI":"10.1073\/pnas.0706832104","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes\/macrophages","volume":"104","author":"Tiemessen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"668349","DOI":"10.3389\/fonc.2021.668349","article-title":"CAFs interacting with TAMs in tumor microenvironment to enhance tumorigenesis and immune evasion","volume":"11","author":"Gunaydin","year":"2021","journal-title":"Front Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","article-title":"Current status of interleukin-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat Immunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"108469","DOI":"10.1016\/j.intimp.2021.108469","article-title":"Immunotherapy of cancer by targeting regulatory T cells","volume":"104","author":"Chen","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"805875","DOI":"10.1155\/2012\/805875","article-title":"The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis","volume":"2012","author":"Gol-Ara","year":"2012","journal-title":"Arthritis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.coi.2009.09.011","article-title":"Regulatory T cells and inhibitory cytokines in autoimmunity","volume":"21","author":"Bettini","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"ref36","first-page":"73","article-title":"Regulatory T cell-based therapies for autoimmunity","volume":"22","author":"Arellano","year":"2016","journal-title":"Discov Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/eji.201040979","article-title":"PD-L1 expression on tolerogenic APCs is controlled by STAT-3","volume":"41","author":"W\u00f6lfle","year":"2011","journal-title":"Eur J Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2337\/diabetes.54.5.1407","article-title":"Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes","volume":"54","author":"Brusko","year":"2005","journal-title":"Diabetes"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J Exp Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/83784","article-title":"Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse","volume":"27","author":"Brunkow","year":"2001","journal-title":"Nat Genet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2012.09.010","article-title":"T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development","volume":"37","author":"Ohkura","year":"2012","journal-title":"Immunity"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.4049\/jimmunol.1002502","article-title":"CD2 Costimulation reveals defective activity by human CD4+CD25hi Regulatory cells in patients with multiple sclerosis","volume":"186","author":"Baecher-Allan","year":"2011","journal-title":"J Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.med.57.121304.131337","article-title":"CD4+CD25+ regulatory T cells and their therapeutic potential","volume":"57","author":"Randolph","year":"2006","journal-title":"Annu Rev Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","article-title":"Regulatory cells and the effect of cancer immunotherapy","volume":"22","author":"Iglesias-Escudero","year":"2023","journal-title":"Mol Cancer"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd3683","article-title":"Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer","volume":"12","author":"von Boehmer","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/0008-5472.CAN-18-1351","article-title":"Treg destabilization and reprogramming: implications for cancer immunotherapy","volume":"78","author":"Munn","year":"2018","journal-title":"Cancer Res"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"717421","DOI":"10.3389\/fimmu.2021.717421","article-title":"Lineage reprogramming of effector regulatory T cells in cancer","volume":"12","author":"Dixon","year":"2021","journal-title":"Front Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cell.2017.08.004","article-title":"NF-\u03baB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer","volume":"170","author":"Grinberg-Bleyer","year":"2017","journal-title":"Cells"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.immuni.2016.10.021","article-title":"Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells","volume":"45","author":"De Simone","year":"2016","journal-title":"Immunity"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1182\/blood-2007-07-097642","article-title":"OX40 costimulation and regulatory T cells","volume":"110","author":"Kupiec-Weglinski","year":"2007","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ijc.24435","article-title":"OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity","volume":"125","author":"Kitamura","year":"2009","journal-title":"Int J Cancer"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fcell.2021.692982","article-title":"Boosting antitumor response by costimulatory strategies driven to 4-1BB and OX40 T-cell receptors","volume":"9","author":"Mascarelli","year":"2021","journal-title":"Front Cell Develop Biol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1021\/acsbiomaterials.1c01637","article-title":"In situ reprogramming of tumors for activating the OX40\/OX40 ligand checkpoint pathway and boosting antitumor immunity","volume":"9","author":"Gao","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/esmoopen-2019-000573","article-title":"New pathways in immune stimulation: targeting OX40","volume":"5","author":"Alves Costa Silva","year":"2020","journal-title":"ESMO Open"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"43003","DOI":"10.1038\/srep43003","article-title":"Single CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells","volume":"7","author":"He","year":"2017","journal-title":"Sci Rep"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.4049\/jimmunol.171.7.3348","article-title":"Cutting edge: CD28 controls peripheral homeostasis of CD4+ CD25+ regulatory T cells","volume":"171","author":"Tang","year":"2003","journal-title":"J Immunol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14712598.2017.1333595","article-title":"Challenges and opportunities in targeting the CD28\/CTLA-4 pathway in transplantation and autoimmunity","volume":"17","author":"Crepeau","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.4049\/jimmunol.0903933","article-title":"Cutting edge: CD28 and c-rel\u2013dependent pathways initiate regulatory T cell development","volume":"184","author":"Vang","year":"2010","journal-title":"J Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.immuni.2017.08.014","article-title":"Driving Rel-iant Tregs toward an identity crisis","volume":"47","author":"Li","year":"2017","journal-title":"Immunity"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cell.2017.08.004","article-title":"NF-\u03baB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer","volume":"170","author":"Grinberg-Bleyer","year":"2017","journal-title":"Cells"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1215-2","article-title":"Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy","volume":"570","author":"Di Pilato","year":"2019","journal-title":"Nature"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1172\/JCI99760","article-title":"Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy","volume":"128","author":"Goswami","year":"2018","journal-title":"J Clin Invest"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"20763","DOI":"10.1038\/s41598-021-00325-3","article-title":"Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients","volume":"11","author":"Marable","year":"2021","journal-title":"Sci Rep"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41422-018-0012-z","article-title":"Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1073\/pnas.0813175106","article-title":"Anti-CTLA-4 therapy results in higher CD4+ ICOShi T cell frequency and IFN-\u03b3 levels in both nonmalignant and malignant prostate tissues","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"ref70","first-page":"503","article-title":"Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use","volume":"37","author":"Fellner","year":"2012","journal-title":"P T"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/978-0-387-89520-8_11","article-title":"GITR: a modulator of immune response and inflammation","volume":"647","author":"Nocentini","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00262-010-0866-5","article-title":"Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy","volume":"59","author":"Coe","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1038\/s41467-021-22885-8","article-title":"Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas","volume":"12","author":"Amoozgar","year":"2021","journal-title":"Nat Commun"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"viii411","DOI":"10.1093\/annonc\/mdy288.027","article-title":"A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors","volume":"29","author":"Denlinger","year":"2018","journal-title":"Ann Oncol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-018-0407-x","article-title":"Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors","volume":"6","author":"Tran","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaoncol.2019.3848","article-title":"Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor-related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors: a phase 1\/2a dose-escalation and cohort-expansion clinical trial","volume":"6","author":"Heinhuis","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref77","unstructured":"Phase I\/Ib study of GWN323 alone and in combination with PDR001 in patients with advanced malignancies and lymphomas"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","article-title":"Rational design of anti-GITR-based combination immunotherapy","volume":"25","author":"Zappasodi","year":"2019","journal-title":"Nat Med"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1084\/jem.20050940","article-title":"Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells","volume":"202","author":"Ko","year":"2005","journal-title":"J Exp Med"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2014.07.031","article-title":"Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus","volume":"158","author":"Feng","year":"2014","journal-title":"Cells"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"134ra62","DOI":"10.1126\/scitranslmed.3003330","article-title":"CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients","volume":"4","author":"Rech","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and beyond in cancer immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J Interf Cytokine Res"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1046\/j.1365-2125.1998.00036.x","article-title":"Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application","volume":"46","author":"Kirchner","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"e003155","DOI":"10.1136\/jitc-2021-003155","article-title":"Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate","volume":"10","author":"Rosemina","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7497\/j.issn.2095-3941.2014.01.001","article-title":"Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies","volume":"11","author":"Phan","year":"2014","journal-title":"Cancer Biol Med"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cells"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metab"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/0008-5472.CAN-18-1351","article-title":"Treg destabilization and reprogramming: implications for Cancer immunotherapy","volume":"78","author":"Munn","year":"2018","journal-title":"Cancer Res"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1189\/jlb.2AB0514-273RR","article-title":"Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells","volume":"97","author":"Basu","year":"2015","journal-title":"J Leukoc Biol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","article-title":"Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN","volume":"95","author":"Stambolic","year":"1998","journal-title":"Cells"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"e1500845","DOI":"10.1126\/sciadv.1500845","article-title":"The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment","volume":"1","author":"Sharma","year":"","journal-title":"Sci Adv"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/ni.3076","article-title":"Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses","volume":"16","author":"Shrestha","year":"2015","journal-title":"Nat Immunol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1096\/fj.14-268409","article-title":"Essential role of mitochondrial energy metabolism in Foxp3+ T-regulatory cell function and allograft survival","volume":"29","author":"Beier","year":"2015","journal-title":"FASEB J"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2016.07.032","article-title":"Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche","volume":"166","author":"Clever","year":"2016","journal-title":"Cells"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.immuni.2015.05.016","article-title":"E3 ubiquitin ligase VHL regulates hypoxia-inducible factor-1\u03b1 to maintain Regulatory T cell stability and suppressive capacity","volume":"42","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","article-title":"Interferon-\u03b3 drives T(reg) fragility to promote anti-tumor immunity","volume":"169","author":"Overacre-Delgoffe","year":"2017","journal-title":"Cells"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1084\/jem.20110278","article-title":"HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J Exp Med"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cmet.2019.11.021","article-title":"Mitochondrial integrity regulated by lipid metabolism is a cell-intrinsic checkpoint for Treg suppressive function","volume":"31","author":"Field","year":"2020","journal-title":"Cell Metab"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"E6546","DOI":"10.1073\/pnas.1720113115","article-title":"Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth","volume":"115","author":"Pacella","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41590-020-0601-0","article-title":"CD36 \u2014 the Achilles\u2019 heel of Treg cells","volume":"21","author":"Horton","year":"2020","journal-title":"Nat Immunol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","article-title":"CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors","volume":"21","author":"Wang","year":"2020","journal-title":"Nat Immunol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-021-03235-6","article-title":"Lipid signalling enforces functional specialization of Treg cells in tumours","volume":"591","author":"Lim","year":"2021","journal-title":"Nature"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/s41467-023-37614-6","article-title":"Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction","volume":"14","author":"Gong","year":"2023","journal-title":"Nat Commun"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.immuni.2021.04.014","article-title":"Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential","volume":"54","author":"Procaccini","year":"2021","journal-title":"Immunity"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.immuni.2019.10.001","article-title":"Amino acids license kinase mTORC1 activity and Treg cell function via small G proteins rag and Rheb","volume":"51","author":"Shi","year":"2019","journal-title":"Immunity"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"886822","DOI":"10.3389\/fimmu.2022.886822","article-title":"Immunometabolism \u2013 the role of branched-chain amino acids","volume":"13","author":"Yahsi","year":"2022","journal-title":"Front Immunol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.celrep.2017.10.082","article-title":"Slc3a2 mediates branched-chain amino-acid-dependent maintenance of regulatory T cells","volume":"21","author":"Ikeda","year":"2017","journal-title":"Cell Rep"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12032-022-01724-w","article-title":"The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies","volume":"39","author":"Hosseinalizadeh","year":"2022","journal-title":"Med Oncol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.2174\/092986711795656045","article-title":"Indoleamine 2,3-dioxygenase, Tregs and cancer","volume":"18","author":"Munn","year":"2011","journal-title":"Curr Med Chem"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ni.3365","article-title":"Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis","volume":"17","author":"Wei","year":"2016","journal-title":"Nat Immunol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s11658-023-00418-z","article-title":"TRIM8: a double-edged sword in glioblastoma with the power to heal or hurt","volume":"28","author":"Hosseinalizadeh","year":"2023","journal-title":"Cell Mol Biol Lett"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1084\/jem.20180397","article-title":"Metabolic control of regulatory T cell stability and function by TRAF3IP3 at the lysosome","volume":"215","author":"Yu","year":"2018","journal-title":"J Exp Med"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ni.3365","article-title":"Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis","volume":"17","author":"Wei","year":"2016","journal-title":"Nat Immunol"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"909705","DOI":"10.3389\/fimmu.2022.1081546","article-title":"Regulation of Treg cell metabolism and function in non-lymphoid tissues","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3390\/cells8111387","article-title":"Regulatory T cells induce metastasis by increasing Tgf-\u03b2 and enhancing the epithelial\u2013mesenchymal transition","volume":"8","author":"Oh","year":"2019","journal-title":"Cells"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-16-2848","article-title":"Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma T-cell immunophenotype in renal cell carcinoma","volume":"23","author":"Giraldo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10549-013-2556-4","article-title":"FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast","volume":"139","author":"Lal","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"e74430","DOI":"10.1371\/journal.pone.0074430","article-title":"CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL\u2013RANK signalling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","article-title":"Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice","volume":"23","author":"Ahern","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: anti-RANKL antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr Osteoporos Rep"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"104193","DOI":"10.1016\/j.cellimm.2020.104193","article-title":"Regulatory T cell therapy: current and future design perspectives","volume":"356","author":"Rana","year":"2020","journal-title":"Cell Immunol"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12672-022-00567-1","article-title":"Natural killer cell immunotherapy in glioblastoma","volume":"13","author":"Hosseinalizadeh","year":"2022","journal-title":"Discover Oncol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11427-022-2212-5","article-title":"CARs: a new approach for the treatment of autoimmune diseases","volume":"66","author":"Sun","year":"2022","journal-title":"Sci China Life Sci"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"ref133","unstructured":""},{"key":"ref134","unstructured":""},{"key":"ref135","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2337\/diabetes.54.1.92","article-title":"Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes","volume":"54","author":"Lindley","year":"2005","journal-title":"Diabetes"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"MON","DOI":"10.1210\/js.2019-MON-LB033","article-title":"MON-LB033 unleashing the anti-inflammatory potential of Treg cells against type I diabetes using advanced chimeric antigen receptor technology","volume":"3","author":"Imam","year":"2019","journal-title":"J Endocr Soc"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"10991","DOI":"10.1038\/ncomms10991","article-title":"Type 1 diabetes vaccine candidates promote human Foxp3+Treg induction in humanized mice","volume":"7","author":"Serr","year":"2016","journal-title":"Nat Commun"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41467-017-02406-2","article-title":"Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis","volume":"9","author":"Kimura","year":"2018","journal-title":"Nat Commun"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1056\/NEJMcibr2033544","article-title":"Cells in multiple sclerosis","volume":"384","author":"Goverman","year":"2021","journal-title":"N Engl J Med"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"e140690","DOI":"10.1172\/JCI140690","article-title":"Prostaglandin I2 signaling licenses Treg suppressive function and prevents pathogenic reprogramming","volume":"131","author":"Norlander","year":"2021","journal-title":"J Clin Invest"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"661875","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front Immunol"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/eji.200839073","article-title":"Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg","volume":"39","author":"Stephens","year":"2009","journal-title":"Eur J Immunol"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J Autoimmun"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J Autoimmun"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"102401","DOI":"10.1016\/j.jaut.2020.102401","article-title":"Treatment of experimental autoimmune encephalomyelitis with engineered bi-specific Foxp3+ regulatory CD4+ T cells","volume":"108","author":"Malviya","year":"2020","journal-title":"J Autoimmun"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.4049\/jimmunol.0904044","article-title":"TGF-\u03b2\u2013induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis","volume":"184","author":"Zhang","year":"2010","journal-title":"J Immunol"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"19078","DOI":"10.1073\/pnas.0907396106","article-title":"Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis","volume":"106","author":"Wright","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","article-title":"The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease","volume":"148","author":"Afzali","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41556-022-00853-8","article-title":"Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses","volume":"24","author":"Chen","year":"2022","journal-title":"Nat Cell Biol"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41467-023-36594-x","article-title":"Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming","volume":"14","author":"Aso","year":"2023","journal-title":"Nat Commun"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3389\/fimmu.2020.00348","article-title":"Transcriptional regulators of T helper 17 cell differentiation in health and autoimmune diseases","volume":"11","author":"Capone","year":"2020","journal-title":"Front Immunol"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/mi.2012.6","article-title":"ROR\u03b3t-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation","volume":"5","author":"Kanai","year":"2012","journal-title":"Mucosal Immunol"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12016-021-08866-1","article-title":"Improving the efficacy of regulatory T cell therapy","volume":"62","author":"Baeten","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4049\/jimmunol.1200633","article-title":"Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity","volume":"189","author":"Haque","year":"2012","journal-title":"J Immunol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.4049\/jimmunol.180.7.4476","article-title":"Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways","volume":"180","author":"Jacobs","year":"2008","journal-title":"J Immunol"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"e0275777","DOI":"10.1371\/journal.pone.0275777","article-title":"Triggering of lymphocytes by CD28, 4-1BB, and PD-1 checkpoints to enhance the immune response capacities","volume":"17","author":"Kaviani","year":"2022","journal-title":"PLoS One"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"367ra166","DOI":"10.1126\/scitranslmed.aag3187","article-title":"Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2","volume":"8","author":"Arenas-Ramirez","year":"2016","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1244298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:18:24Z","timestamp":1695860304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1244298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":161,"alternative-id":["10.3389\/fmed.2023.1244298"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1244298","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"article-number":"1244298"}}